Clinical Trials Logo

Clinical Trial Summary

In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination. Surgery in combination with chemotherapy is another option. For patients who are not medically fit for surgery or with unresectable invasion in adjacent structures the only alternative with curative intent is, with current knowledge, definitive chemoradiotherapy. In the current study the investigators aim to improve prognosis for patients not suitable for surgery. Patients receive treatment with conventional chemoradiotherapy (oxaliplatin, fluorouracil and radiotherapy) with the addition of a more recently developed drug, an antibody called cetuximab.


Clinical Trial Description

Patients are treated with three cycles of oxaliplatin and fluorouracil 750 mg/m2/24 hours, day 1-5. Each cycle lasts for 21 days. Oxaliplatin is given with 130 mg/m2 in the first cycle and in cycle 2 and 3 which are administered concomitant with radiotherapy the dose is reduced to 85 mg/m2.

A loading dose of cetuximab 400 mg/m2 is given one week before the start of radiotherapy, and thereafter 250 mg/m2 is given weekly during the course of radiotherapy.

Concomitant with chemotherapy radiotherapy to a total dose of 50 Gy is given (2 Gy once daily in 25 fractions, 5 days a week) with a photon beam linear accelerator.

After treatment patients are followed every 6 months for three years with clinical examination and a CT-scan. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02636088
Study type Interventional
Source Karolinska University Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 2011
Completion date January 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05406024 - Feasibility Study CORPPS
Terminated NCT02601079 - Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis N/A
Active, not recruiting NCT01745107 - Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Phase 3
Active, not recruiting NCT02969473 - Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT00288119 - Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Terminated NCT01870791 - Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer Phase 2
Active, not recruiting NCT00431756 - Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Not yet recruiting NCT05736705 - Monopolar and Bipolar in Esophageal ESD N/A
Completed NCT02395705 - Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Phase 3
Completed NCT02033213 - Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial N/A
Terminated NCT00653107 - Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only Phase 3
Completed NCT01927016 - Outcomes After Esophageal Cancer Surgery N/A
Completed NCT02558504 - Radiofrequency in the Treatment of Barrett's Oesophagus Phase 4
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Completed NCT00318903 - Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Phase 2
Recruiting NCT02583087 - ESD for the Treatment of Early Barrett's Neoplasia N/A
Active, not recruiting NCT04489368 - Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning